Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J. A. Ledermann1, F. A. Raja1, C. Fotopoulou2, A. Gonzalez-Martin3, N. Colombo4 & C. Sessa5, on behalf of the ESMO Guidelines Working Group* UCL Cancer Institute, University College London, London; Imperial College, London, UK; MD Anderson Cancer Centre, Madrid, Spain; European Institute of Oncology, University of Milan Bicocca, Milan, Italy; Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

[1]  J. Sehouli,et al.  Value of Tertiary Cytoreductive Surgery in Epithelial Ovarian Cancer: An International Multicenter Evaluation , 2013, Annals of Surgical Oncology.

[2]  A. Malpica,et al.  Ovarian low-grade serous carcinoma: a comprehensive update. , 2012, Gynecologic oncology.

[3]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Reuss,et al.  AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Jobo,et al.  Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. , 2012 .

[6]  D. Miller,et al.  Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? , 2012, American journal of obstetrics and gynecology.

[7]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[8]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[9]  A. Brandes,et al.  Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Berek,et al.  Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort , 2011, British Journal of Cancer.

[11]  W. McCluggage,et al.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.

[12]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[14]  D. Alberts,et al.  Clinical Trials in Recurrent Ovarian Cancer , 2011, International Journal of Gynecologic Cancer.

[15]  M. Parmar,et al.  Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) , 2010, International Journal of Gynecologic Cancer.

[16]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[17]  B. Monk,et al.  Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  V. Gebski,et al.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Monk,et al.  Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Reuss,et al.  Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Reuss,et al.  Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.

[22]  A. Zwinderman,et al.  Understanding the problem of inadequately staging early ovarian cancer. , 2010, European journal of cancer.

[23]  B. Monk,et al.  The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.

[24]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[25]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[26]  W. Cliby,et al.  Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. , 2009, Journal of the American College of Surgeons.

[27]  D. Alberts,et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Jacobus Pfisterer,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[29]  S. Loibl,et al.  Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis , 2009, Annals of Surgical Oncology.

[30]  D. Bodurka,et al.  Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. , 2008, Gynecologic oncology.

[31]  A. Swart.  Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1) , 2007 .

[32]  D. Alberts,et al.  A meta‐analysis of the efficacy of intraperitoneal cisplatin for the front‐line treatment of ovarian cancer , 2007, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[33]  V. Torri,et al.  Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis , 2006, British Journal of Cancer.

[34]  R. Hariprasad,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[35]  Wing H Wong,et al.  Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. , 2005, Cancer research.

[36]  N. Hacker,et al.  Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. , 2005, Journal of the National Cancer Institute.

[37]  S. Rubin,et al.  Secondary surgical cytoreduction for advanced ovarian carcinoma. , 2004, The New England journal of medicine.

[38]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. V. van Houwelingen,et al.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Scully.  Histological Typing of Ovarian Tumours , 1999, World Health Organization. International Histological Classification of Tumours.

[41]  M. Buyse,et al.  The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.

[42]  D. Alberts,et al.  PLATINUM COMBINATION CHEMOTHERAPY VERSUS PLATINUM MONOTHERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A META-ANALYSIS OF RANDOMISED TRIALS USING INDIVIDUAL PATIENT DATA (IPD) , 2012 .

[43]  H. Kitchener,et al.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. , 2012, The Cochrane database of systematic reviews.

[44]  J. Thigpen.  Reclassification of Serous Ovarian Carcinoma by a 2-Tier System: A Gynecologic Oncology Group Study , 2012 .

[45]  J. Thigpen.  Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention , 2009 .

[46]  G. Rustin,et al.  A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Thigpen.  Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma , 2006 .

[48]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. , 2003, Lancet.

[49]  B. Karlan,et al.  Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. , 2001, Gynecologic oncology.

[50]  S. Silverberg.  Toward the development of a universal grading system for ovarian epithelial carcinoma. , 1999, Gynecologic oncology.

[51]  I. Timor-Tritsch,et al.  Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. , 1994, American journal of obstetrics and gynecology.

[52]  Gerhard Jentzsch,et al.  Working group on , 1991 .

[53]  C A SALVATORE,et al.  [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.